Meet Alfa Cytology at the Cancer R&D 2024, Nov 18-20, 2024. We look forward to connecting with you and providing expert solutions for your cancer drug development projects.

Learn More
Solutions
Online Inquiry

Imaging Services for Tumor Stroma

Tumor stroma imaging has emerged as a revolutionary tool in cancer research and treatment by providing valuable insights into the complexities of the tumor microenvironment (TME). Alfa Cytology is revolutionizing this field through its advanced imaging services.

The Study of Tumor Stroma

TME, consisting of tumor cells and the surrounding stroma, is a complex ecosystem that plays a critical role in tumor development, progression, and treatment response. The tumor stroma is a dynamic and heterogeneous environment that influences tumor growth, metastasis, and response to therapy. It consists of various components, including blood vessels, immune cells, fibroblasts, and extracellular matrix. Altered metabolic processes and intercellular signaling pathways within the stroma contribute significantly to tumor behavior and treatment resistance. Understanding the characteristics and interactions within the tumor stroma is essential for advancing our knowledge of cancer biology and developing personalized treatment strategies.

Major components of the tumor stroma and their tumor-promoting functions.Fig.1 Major components of the tumor stroma and their tumor-promoting functions. (Xu, M., et al., 2022)

Our Services

Besides providing a comprehensive analysis of the entire tumor microenvironment, Alfa Cytology specializes in conducting focused assessment of specific stromal characteristics, such as immune cells, cancer-associated fibroblasts, and cytokines. We employ advanced quantitative analysis techniques to extract meaningful information from tumor stroma imaging data. Focusing on these specific elements of the tumor microenvironment, we are capable of unraveling the intricate interactions between malignant tumor cells and their surrounding stroma. This in-depth analysis allows for a more precise characterization of the TME and can contribute to the individualized therapeutic strategies.

The tumor stroma imaging services we provide include, but are not limited to:

Imaging Services for
Angiogenesis in TME

We assist researchers in assessing various aspects of the angiogenesis in TME, including microvessel density, vascular permeability, perfusion, and angiogenic activity.

Imaging Services for
Cancer-Associated Fibroblasts

By leveraging advanced imaging techniques and employing molecular probes and tracers, we can visualize and characterize the presence, distribution, and activities of CAFs within the TME.

Imaging Services for
Immune Cell Populations in TME

We combine anatomical images with molecular images to provide customers with a more comprehensive analysis of immune cell populations in the tumor microenvironment.

Imaging Services for
Cytokines in TME

Our advanced imaging techniques allow for the visualization and quantification of cytokine expression and localization within the TME.

The Advantages of Our Tumor Stroma Imaging Services

  • We employ advanced imaging techniques that allow us to generate high-resolution images, enabling the identification and quantification of stromal components and their spatial distribution.
  • We utilize a wide range of validated biomarkers to gain deeper insights into the dynamic changes occurring within the tumor stroma and their impact on tumor progression and treatment response.
  • Through sophisticated algorithms and image processing methods, we can quantitatively evaluate parameters related to stromal composition, vascularization, and metabolic activity.
  • We collaborate closely with clients to design imaging protocols that capture the desired information and insights.

At Alfa Cytology, we are dedicated to driving innovation in tumor stroma imaging and making grate contributions to the development of effective targeted therapies. Contact us today to learn more about our imaging services and how they can propel your research forward.

Reference

  1. Xu, M., et al.; (2022). Targeting the tumor stroma for cancer therapy. Molecular Cancer21(1), 208.

For research use only.